---

Referenser

1. Socialstyrelsen. Klassifikationen ICD-10 Stockholm: Socialstyrelsen; 2024 [Available from: https://www.socialstyrelsen.se/statistik-och-data/klassifikationer-och-koder/icd-10/

2. WHO. ICD-11 International Classification of Diseases 11th Revision - The global standard for diagnostic health information Geneve: World Health Organization; 2024 [Available from: https://icd.who.int/en

3. Herlofson J. Mini-D 5 : diagnostiska kriterier enligt DSM-5-TR. Uppsala: Pilgrim press; 2022.

4. Guterstam J, Sandell, M., Heilig. M.,. Nya svenska diagnoskoder för beroendetillstånd i remission Stockholm: Läkartidningen; 2024 [Available from: https://lakartidningen.se/klinik-och-vetenskap-1/kommentar/2024/01/nya-svenska-diagnoskoder-for-beroendetillstand-i-remission/

5. Folkhälsomyndigheten. Den svenska narkotikasituationen 2023 Stockholm: Folkhälsomyndigheten; 2024 [Available from: https://www.folkhalsomyndigheten.se/publikationer-och-material/publikationsarkiv/d/den-svenska-narkotikasituationen-2023/?pub=130513

6. Socialstyrelsen. Senaste version av HSLF-FS 2016:1 Socialstyrelsens föreskrifter och allmänna råd om läkemedelsassisterad behandling vid opioidberoende Stockholm: Socialstyrelsen; 2020 [Available from: https://www.socialstyrelsen.se/kunskapsstod-och-regler/regler-och-riktlinjer/foreskrifter-och-allmanna-rad/konsoliderade-foreskrifter/20161-om-lakemedelsassisterad-behandling-vid-opioidberoende/

7. Gowing L, Farrell M, Ali R, White JM. Alpha₂-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016;2016(5):Cd002024.

8. Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev. 2017;2(2):Cd002025.

9. Santo T, Jr., Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(9):979-93.

10. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188-209.

11. Vikbladh T, Troberg K, Håkansson A, Dahlman D. Healthcare utilization for somatic conditions among Swedish patients in opioid substitution treatment, with and without on-site primary healthcare. BMC Health Serv Res. 2022;22(1):971.

12. Stockings E, Tran LT, Santo T, Jr., Peacock A, Larney S, Santomauro D, et al. Mortality among people with regular or problematic use of amphetamines: a systematic review and meta-analysis. Addiction. 2019;114(10):1738-50.

13. Srisurapanont M, Likhitsathian S, Suttajit S, Maneeton N, Maneeton B, Oon-Arom A, et al. Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis. Drug Alcohol Depend. 2021;219:108467.

14. Fluyau D, Mitra P, Lorthe K. Antipsychotics for Amphetamine Psychosis. A Systematic Review. Front Psychiatry. 2019;10:740.

15. Socialstyrelsen. Nationella riktlinjer: missbruk och beroende Stockholm: Socialstyrelsen; 2019 [Available from: https://www.socialstyrelsen.se/kunskapsstod-och-regler/regler-och-riktlinjer/nationella-riktlinjer/riktlinjer-och-utvarderingar/missbruk-och-beroende/

16. Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis. Addiction. 2019;114(12):2122-36.

17. Naji L, Dennis B, Rosic T, Wiercioch W, Paul J, Worster A, et al. Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis. Drug Alcohol Depend. 2022;232:109295.

18. Konstenius M, Jayaram-Lindström N, Guterstam J, Beck O, Philips B, Franck J. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction. 2014;109(3):440-9.

19. Sundin E. LJ, Ramstedt M., . Negativa konsekvenser av alkohol, narkotika och tobak - CAN rapport 174 Stockholm: Centralförbundet för alkohol- och narkotikaupplysning, CAN; 2018 [Available from: https://www.can.se/publikationer/negativa-konsekvenser-av-alkohol-narkotika-och-tobak/

20. Strand MC, Mørland J, Slørdal L, Riedel B, Innerdal C, Aamo T, et al. Conversion factors for assessment of driving impairment after exposure to multiple benzodiazepines/z-hypnotics or opioids. Forensic Sci Int. 2017;281:29-36.

21. Park TW, Larochelle MR, Saitz R, Wang N, Bernson D, Walley AY. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. Addiction. 2020;115(5):924-32.

22. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5):476-83.

23. Sundin E. Användning och beroendeproblem av alkohol, narkotika och tobak - En studie med fokus på år 2021 i Sverige Stockholm: Centralförbundet för alkohol- och narkotikaupplysning, CAN; 2021 [Available from: https://www.can.se/publikationer/anvandning-och-beroendeproblem-av-alkohol-narkotika-och-tobak/

24. Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1-2):120-30.

25. Feingold D, Livne O, Rehm J, Lev-Ran S. Probability and correlates of transition from cannabis use to DSM-5 cannabis use disorder: Results from a large-scale nationally representative study. Drug Alcohol Rev. 2020;39(2):142-51.

26. Andersson F, Sundin E, Magnusson C, Ramstedt M, Galanti MR. Prevalence of cannabis use among young adults in Sweden comparing randomized response technique with a traditional survey. Addiction. 2023;118(9):1801-10.

27. Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. Association of cannabis potency with mental ill health and addiction: a systematic review. Lancet Psychiatry. 2022;9(9):736-50.

28. Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. Lancet. 1988;1(8592):1000-1.

29. Niemi-Pynttäri JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(1):e94-9.

30. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, et al. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl). 2010;211(2):233-44.

31. Meier MH, Caspi A, A RK, Hall W, Ambler A, Harrington H, et al. Long-Term Cannabis Use and Cognitive Reserves and Hippocampal Volume in Midlife. Am J Psychiatry. 2022;179(5):362-74.